Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].

被引：5

作者：

Kim, Jisun

Han, Wonshik

Kim, Eun-Kyu

Jung, Yongsik

Kim, Hyun-Ah

Chae, Soo Min

Lee, Eun Sook

Ahn, Sei-Hyun

Kim, Tae Hyun

Jeong, Joon

Choi, Su Yun

Nam, Seok Jin

Paik, Nam-Sun

Kim, Lee Su

Gong, Gyungyub

Yu, Jong Han

Jung, So-Youn

Kim, Hee Jeong

Ahn, Sung Gwe

Kim, Min Kyoon

机构：

[1] Asan Med Ctr, Dept Surg, Seoul, South Korea

[2] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea

[3] Seoul Natl Univ, Bundang Hosp, Dept Surg, Seongnam, South Korea

[4] Ajou Univ Hosp, Suwon, South Korea

[5] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Seoul, South Korea

[6] Seoul Natl Univ, Bundang Hosp, Dept Surg, Seoul, South Korea

[7] Natl Canc Ctr, Ctr Breast Canc, Goyang Si, South Korea

[8] Univ Ulsan, Coll Med, Dept Surg, Seoul, South Korea

[9] ASAN Med Ctr, Seoul, South Korea

[10] Inje Univ, Busan Paik Hosp, Dept Surg, Busan, South Korea

[11] Yonsei Univ Hlth Syst, Seoul, South Korea

[12] Hallym Univ, Coll Med, Kangdong Sacred Heart Hosp, Div Breast & Endocrine Surg, Seoul, South Korea

[13] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[14] Ewha Womans Univ, Sch Med, Dept Surg, Seoul, South Korea

[15] Hallym Univ, Coll Med, Sacred Heart Hosp, Div Breast & Endocrine Surg, Anyang, South Korea

[16] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[17] Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea

[18] Gangnam Severance Hosp, Seoul, South Korea

[19] Chung Ang Univ, Coll Med, Dept Surg, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.576

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

576

引用

下载

页数：2

共 50 条

[21] A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
Ademuyiwa, Foluso O.
Northfelt, Donald W.
O'Connor, Tracey
Levine, Ellis
Luo, Jingqin
Tao, Yu
Hoog, Jeremy
Laury, Marie L.
Summa, Tracy
Hammerschmidt, Trish
Guo, Zhanfang
Frith, Ashley
Weilbaecher, Katherine
Opyrchal, Mateusz
Aft, Rebecca
Clifton, Katherine
Suresh, Rama
Bagegni, Nusayba
Hagemann, Ian S.
Iglesia, Michael D.
Ma, Cynthia X.
NPJ BREAST CANCER, 2023, 9 (01)
[22] A phase II parallel group study with letrozole plus goserelin in premenopausal, and letrozole in postmenopausal metastatic breast cancer patients as first line hormone therapy
Ro, J.
Lee, K. S.
Han, H.
Lee, E.
Kang, H. S.
Kim, S. W.
Kwon, Y.
Nam, B.
EJC SUPPLEMENTS, 2008, 6 (07): : 176 - 176
[23] Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER plus breast cancer
Baselga, J.
Semiglazov, V
van Dam, P.
Manikhas, A.
Bellet, M.
Mayordomo, J.
Campone, M.
Kubista, E.
Greil, R.
Bianchi, G.
Steinseifer, J.
Molloy, B.
Tokaji, E.
Dixon, J. M.
Jonat, W.
Rugo, H. S.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S107 - S107
[24] PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer
Kumar, S. S.
Benson, J.
McIntosh, S.
King, P.
Dougall, G.
Kateb, A.
Vallier, A-L
Jones, L.
Qian, W.
Provenzano, E.
Caldas, C.
Pantziarka, P.
Carroll, J.
Baird, R. D.
CANCER RESEARCH, 2019, 79 (04)
[25] Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)
Takahiro Nakayama
Yasuaki Sagara
Tsutomu Takashima
Nobuki Matsunami
Norikazu Masuda
Yasuo Miyoshi
Tetsuya Taguchi
Toyokazu Aono
Toshikazu Ito
Tatsuo Kagimura
Shinzaburo Noguchi
Cancer Chemotherapy and Pharmacology, 2018, 81 : 755 - 762
[26] Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)
Nakayama, Takahiro
Sagara, Yasuaki
Takashima, Tsutomu
Matsunami, Nobuki
Masuda, Norikazu
Miyoshi, Yasuo
Taguchi, Tetsuya
Aono, Toyokazu
Ito, Toshikazu
Kagimura, Tatsuo
Noguchi, Shinzaburo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 755 - 762
[27] Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
Paul, Devchand
Vukelja, Svetislava J.
Holmes, Frankie Ann
Blum, Joanne L.
McIntyre, Kristi J.
Lindquist, Deborah L.
Osborne, Cynthia R.
Sanchez, Ines J.
Goldschmidt, Jerome H.
Wang, Yunfei
Asmar, Lina
Strauss, Lewis
O'Shaughnessy, Joyce
NPJ BREAST CANCER, 2019, 5 (1)
[28] Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
Devchand Paul
Svetislava J. Vukelja
Frankie Ann Holmes
Joanne L. Blum
Kristi J. McIntyre
Deborah L. Lindquist
Cynthia R. Osborne
Ines J. Sanchez
Jerome H. Goldschmidt
Yunfei Wang
Lina Asmar
Lewis Strauss
Joyce O’Shaughnessy
npj Breast Cancer, 5
[29] Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study
Li, Huiping
Zhang, Qingyuan
Li, Wei
Wang, Shusen
Liao, Ning
Shen, Peng
Shao, Bin
Zhao, Wenhui
Sun, Wan
Yan, Ping
Wang, Diane
Li, Vince
Linn, Carlos
Shi, Haihong
O'Gorman, Melissa
Xu, Binghe
LANCET ONCOLOGY, 2017, 18 : S7 - S7
[30] NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole plus /- celecoxib in the treatment of ER positive postmenopausal early breast cancer
Rea, D.
Francis, A.
Poole, C.
Brookes, C.
Stein, R.
Bartlett, J.
Dunn, J.
Canney, P.
Sutton, R.
Daoud, R.
Hallissey, M.
Achuthan, R.
Grant, M.
Babrah, J.
Smith, S.
Fraser, J.
Desai, A.
Al Dubaisi, M.
Patel, A.
Bristol, J.
Chandrasekharan, S.
Prest, C.
Jewkes, A.
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →